aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Allosteros Therapeutics, founded in 2009 and based in Palo Alto, California, focuses on discovering and developing breakthrough small molecule drugs. The company targets allosteric sites on key proteins involved in disease pathways, aiming to create innovative treatments for various medical conditions.
Allosteros Therapeutics has made significant strides in the pharmaceutical industry by advancing its drug development pipeline. The company's pioneering approach has attracted attention and investment, contributing to its growing impact on medical research and treatment options.
Operating Status
Acquired
Ownership Type(s)
Venture Capital, Private
Main Product(s)
Drug Development
Technology
Biotech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
United States
When was Allosteros founded?
Allosteros was founded in 2009.
Where is Allosteros’s headquarters located?
Allosteros’s headquarters is located in Palo Alto, CA, US.
When was Allosteros’s last funding round?
Allosteros’s most recent funding round was for $286k (USD) in August 2012.
How many employees does Allosteros have?
Allosteros has 6 employees as of Feb 4, 2024.
How much has Allosteros raised to-date?
As of July 05, 2023, Allosteros has raised a total of $1.3M (USD) since Aug 20, 2012.
Add Comparison
Total Raised to Date
$1.3M
USD
Last Update Aug 20, 2012
Last Deal Details
$286k
USD
Aug 20, 2012
Debt Financing
Total Employees Over Time
6
As of Feb 2024
Allosteros Address
560 Pena Ct
Palo Alto,
California
94306
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts